
    
      Part I:

      This part of the study is designed to demonstrate the dose equivalence between off-label
      aerosolized epoprostenol and VentaProst using a patient's hemodynamic parameters.

      Part II:

      This part of the study is designed to establish a dose response relationship of VentaProst to
      hemodynamic effect by dose escalation in patients who have had cardiac surgery with CPB.
    
  